Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma
Korean J Intern Med
.
2023 Jul;38(4):578.
doi: 10.3904/kjim.2022.183e.
Epub 2023 Jun 9.
Authors
Hee Jeong Cho
1
,
Jae-Cheol Jo
2
,
Yoo Jin Lee
2
,
Myung Won Lee
3
,
Do Young Kim
4
,
Ho Jin Shin
4
,
Sung Nam Im
5
,
Ji Hyun Lee
6
,
Sung Hwa Bae
7
,
Young Rok Do
8
,
Won Sik Lee
9
,
Min Kyung Kim
10
,
Jina Jung
1
,
Jung Min Lee
1
,
Ju-Hyung Kim
1
,
Dong Won Baek
1
,
Sang-Kyun Sohn
1
,
Joon Ho Moon
1
Affiliations
1
Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea.
2
Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
3
Department of Hematology-Oncology, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea.
4
Department of Hematology-Oncology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.
5
Department of Hematology- Oncology, Inje University Haeundae Paik Hospital, Busan, Korea.
6
Department of Hematology-Oncology, Dong-A University Hospital, Busan, Korea.
7
Department of Hematology-Oncology, Daegu Catholic University Hospital, Daegu Catholic University School of Medicine, Daegu, Korea.
8
Department of Hematology-Oncology, Keimyung University School of Medicine, Daegu, Korea.
9
Department of Hematology-Oncology, Inje University Busan Paik Hospital, Busan, Korea.
10
Department of Hematology-Oncology, Yeungnam University Hospital, Daegu, Korea.
PMID:
37291840
PMCID:
PMC10338245
DOI:
10.3904/kjim.2022.183e
No abstract available
Publication types
Published Erratum